Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
Seeking Alpha

Regenxbio's Vector Technology Will Change Gene Therapy

Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...
GEN

Vector Production Would Benefit from Purpose-Built Processing Technology

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...
Yahoo Finance

Viral Vector Vaccines Strategic Business Research Report 2025 | Market to Reach $893.2 Million by 2030 - Pandemic-Era Acceleration of Vaccine Technologies Continues to Drive ...

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Viral Vector ...
TMCnet

Vector Capital Completes Acquisition of Showpad

Vector Capital Management, L.P. ("Vector Capital"), a leading technology-focused investment firm, today announced the completion of its acquisition of Showpad, a leader in AI revenue enablement ...